Welcome to our dedicated page for Inmed Pharmaceuticals news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on Inmed Pharmaceuticals stock.
InMed Pharmaceuticals Inc (INM) is a clinical-stage biopharmaceutical leader developing cannabinoid-based therapies for complex medical conditions. This dedicated news hub provides investors and industry observers with timely updates on INM's research milestones, regulatory developments, and strategic initiatives.
Access comprehensive coverage of the company's progress in neurodegenerative, ocular, and dermatological drug development. Our curated news collection features official press releases alongside verified third-party analysis, offering a complete picture of INM's pipeline advancements and intellectual property developments.
Key updates include clinical trial results, regulatory submissions, partnership announcements, and manufacturing innovations related to INM-755, INM-089, and other proprietary candidates. The resource emphasizes INM's unique approach combining cannabinoid pharmacology with advanced delivery systems to address unmet medical needs.
Bookmark this page for streamlined access to essential updates about INM's therapeutic pipeline, patent portfolio expansions, and scientific presentations. Stay informed about the company's progress in developing small molecule therapies through this centralized, regularly updated resource.
InMed Pharmaceuticals (NASDAQ: INM) has published a peer-reviewed study in Biofactors demonstrating cannabinol's (CBN) anti-inflammatory effects and its potential for treating skin diseases. The research, conducted with Dr. Mauro Maccarrone, shows that CBN prevents keratinocyte inflammation through various mechanisms, including TRPV1 receptor activation and modulation of endocannabinoid system elements. The study revealed CBN's ability to reduce pro-inflammatory cytokines while increasing anti-inflammatory ones, supporting its therapeutic potential for conditions like psoriasis, atopic dermatitis, and pruritus.
InMed Pharmaceuticals (NASDAQ: INM) reported Q1 fiscal 2025 results with notable progress in pharmaceutical programs. BayMedica commercial business generated revenues of $1.3M, a 40% increase from last year, with net income of $0.3M. Research and development expenses decreased to $0.8M from $1.3M year-over-year. The company's cash position was $5.6M as of September 30, 2024.
Key developments include positive behavioral data from INM-901 Alzheimer's treatment candidate's long-term preclinical studies and implementation of a reverse stock split to maintain Nasdaq compliance. The company expects current cash to fund operations through Q1 2025.
InMed Pharmaceuticals (NASDAQ: INM) has announced a 1-for-20 share consolidation to regain compliance with Nasdaq's listing requirements. The consolidation will reduce outstanding shares from 14,361,550 to approximately 718,078 common shares. The post-consolidation shares are expected to begin trading on Nasdaq Capital Market on November 15, 2024. The trading symbol 'INM' will remain unchanged. Exercise prices and number of shares for outstanding options, warrants, and convertible securities will be adjusted proportionally. No fractional shares will be issued, with fractions less than half being cancelled and those half or greater rounded up.
InMed Pharmaceuticals (NASDAQ: INM) has received approval from the Nasdaq Listing Qualifications Panel for an exception until December 2, 2024, to implement a share consolidation to meet listing requirements. The company must achieve a minimum $1.00 bid price for ten consecutive trading days by this date. The Board has approved a 20:1 share consolidation, which will reduce outstanding shares from 14,361,550 to approximately 718,078. This consolidation aims to maintain Nasdaq listing compliance while preserving shareholders' proportional ownership. The consolidation will adjust all outstanding securities, including options and warrants, proportionally.
InMed Pharmaceuticals (NASDAQ: INM) has filed an additional international Patent Cooperation Treaty (PCT) application for its drug candidate INM-901, targeting neurodegenerative diseases, including Alzheimer's disease. The patent covers treatment methods for neuronal disorders, cytotoxicity reduction, and neurite regeneration. INM-901 is a small molecule drug showing multiple mechanisms of action, including reduced neuroinflammation, improved neurite growth, and neuroprotective effects through CB1/CB2 receptor activation. The drug can be administered orally and has demonstrated improvements in cognitive function, memory, and behavioral aspects in preclinical studies.
InMed Pharmaceuticals (NASDAQ: INM) announced its participation in an upcoming Fierce Biotech webinar titled 'Alzheimer's Outlook - Neuroinflammation, the Next Step' scheduled for November 12th, 2024, at 2:00pm ET. Dr. Eric Hsu, Senior VP of Preclinical R&D at InMed, will join a distinguished panel of experts to discuss Alzheimer's disease research and neuroinflammation.
The webinar will cover important topics including latest Alzheimer's research, therapeutic pathways, drug development, and neuroinflammation's pathophysiological effects. Notable speakers include Dr. Phyllis Ferrell (moderator), Dr. Barry Greenberg, Dr. David Morgan, Dr. Marwan Sabbagh, and Dr. Eric Hsu.
InMed Pharmaceuticals Inc. (NASDAQ: INM) has appointed Dr. Barry Greenberg to its Scientific Advisory Board. Dr. Greenberg is the Director of the Alzheimer's Disease Translational Center and an Associate Professor in the Department of Neurology at the Johns Hopkins University School of Medicine. With four decades of experience in Alzheimer's disease research, Dr. Greenberg's expertise is expected to be invaluable as InMed advances its INM-901 drug candidate towards human clinical trials in Alzheimer's disease.
Dr. Greenberg has held various positions in the US, Sweden, and Canada, including roles at AstraZeneca and Neurochem, Inc. He has been involved in Alzheimer's disease research and drug discovery since 1985 and has contributed to developing strategies to delay the onset and progression of the disease. At Johns Hopkins, he leads the development of an AD Translational Center, focusing on integrating basic and clinical research to enable the development of effective therapies for Alzheimer's disease.
InMed Pharmaceuticals reported financial results for fiscal year 2024 and provided a business update. Key highlights include:
- $4.6M in revenues, an 11% increase over the previous year
- Net loss of $7.7M, compared to $7.9M in the previous year
- Cash position of $6.6M as of June 30, 2024
- Advancement of INM-901 program for Alzheimer's disease
- Development of INM-089 for Age-Related Macular Degeneration (AMD)
- Strengthened patent portfolio with three new U.S. patents
The company made significant progress in its pharmaceutical pipeline, focusing on Alzheimer's disease and dry AMD. INM-901 demonstrated multiple mechanisms of action and potential disease-modifying effects in preclinical studies. INM-089 showed positive pharmacological effects in dry AMD treatment.
InMed Pharmaceuticals Inc. (NASDAQ: INM) has requested a hearing before the Nasdaq Listing Qualifications Panel to appeal the determination by the Nasdaq Staff regarding the company's non-compliance with the minimum bid price requirement of $1.00 for continued listing on the Nasdaq Capital Market. The hearing is scheduled for October 31, 2024.
InMed had previously been granted a 180-day compliance period until September 16, 2024, to regain compliance. The company received a delisting notice on September 17, 2024, indicating it did not meet the requirement by the compliance date. The appeal has stayed any delisting or suspension action pending the Panel's final decision.
The Panel has discretionary authority to grant InMed up to an additional 180 calendar days from September 16, 2024, to regain compliance. However, there is no guarantee of a favorable outcome for the company.
InMed Pharmaceuticals (NASDAQ: INM) has strengthened its patent portfolio with the issuance of three U.S. patents. These patents cover formulation and method of use for treating epidermolysis bullosa, biosynthesis manufacturing processes, and an ocular drug delivery formulation. The company now has 13 patent families covering various aspects of its drug development programs.
Key highlights include:
- A method of use patent for INM-755, which has completed a Phase 2 clinical trial for epidermolysis bullosa
- A biosynthesis patent for manufacturing proprietary analogs
- An ocular drug delivery formulation patent granted in multiple jurisdictions
InMed continues to pursue patents for its INM-901 program in Alzheimer's disease and INM-089 in dry Age-related Macular Degeneration.
FAQ
What is the current stock price of Inmed Pharmaceuticals (INM)?
What is the market cap of Inmed Pharmaceuticals (INM)?
